BIOG B Stock Overview
BioGaia AB (publ), a healthcare company, develops, markets, and sells probiotic products with documented health benefits worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
BioGaia AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr99.05 |
52 Week High | kr119.40 |
52 Week Low | kr68.88 |
Beta | 0.71 |
1 Month Change | -2.61% |
3 Month Change | -12.11% |
1 Year Change | 27.40% |
3 Year Change | -12.03% |
5 Year Change | 12.30% |
Change since IPO | 1,153.80% |
Recent News & Updates
Recent updates
Calculating The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)
Sep 13Does BioGaia (STO:BIOG B) Deserve A Spot On Your Watchlist?
Jun 02A Look At The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)
Apr 27Do BioGaia's (STO:BIOG B) Earnings Warrant Your Attention?
Jan 14Do BioGaia's (STO:BIOG B) Earnings Warrant Your Attention?
Aug 26Does This Valuation Of BioGaia AB (publ) (STO:BIOG B) Imply Investors Are Overpaying?
Jul 24Calculating The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)
Apr 02BioGaia's (STO:BIOG B) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 21Need To Know: Analysts Are Much More Bullish On BioGaia AB (publ) (STO:BIOG B) Revenues
Feb 09BioGaia's (STO:BIOG B) Upcoming Dividend Will Be Larger Than Last Year's
Feb 07Some Shareholders May find It Hard To Increase BioGaia AB (publ)'s (STO:BIOG B) CEO Compensation This Year
Apr 29Key Things To Consider Before Buying BioGaia AB (publ) (STO:BIOG B) For Its Dividend
Mar 25The BioGaia (STO:BIOG B) Share Price Is Up 90% And Shareholders Are Holding On
Mar 04CEO & President Isabelle Valerie Ducellier Just Bought 8.2% More Shares In BioGaia AB (publ) (STO:BIOG B)
Feb 11Is BioGaia AB (publ)'s (STO:BIOG B) Latest Stock Performance A Reflection Of Its Financial Health?
Jan 26What Type Of Shareholders Own The Most Number of BioGaia AB (publ) (STO:BIOG B) Shares?
Jan 11How Much Are BioGaia AB (publ) (STO:BIOG B) Insiders Taking Off The Table?
Dec 27Read This Before Buying BioGaia AB (publ) (STO:BIOG B) For Its Dividend
Dec 13BioGaia (STO:BIOG B) Shareholders Have Enjoyed A 57% Share Price Gain
Nov 28Shareholder Returns
BIOG B | SE Biotechs | SE Market | |
---|---|---|---|
7D | 6.9% | 0.2% | -1.3% |
1Y | 27.4% | 5.6% | 11.1% |
Return vs Industry: BIOG B exceeded the Swedish Biotechs industry which returned 5.6% over the past year.
Return vs Market: BIOG B exceeded the Swedish Market which returned 11.1% over the past year.
Price Volatility
BIOG B volatility | |
---|---|
BIOG B Average Weekly Movement | 4.6% |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 6.1% |
10% most volatile stocks in SE Market | 11.8% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: BIOG B is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: BIOG B's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 215 | Isabelle Valerie Ducellier | https://www.biogaia.com |
BioGaia AB (publ), a healthcare company, develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula.
BioGaia AB (publ) Fundamentals Summary
BIOG B fundamental statistics | |
---|---|
Market Cap | kr10.00b |
Earnings (TTM) | kr415.42m |
Revenue (TTM) | kr1.21b |
24.1x
P/E Ratio8.2x
P/S RatioIs BIOG B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BIOG B income statement (TTM) | |
---|---|
Revenue | kr1.21b |
Cost of Revenue | kr330.33m |
Gross Profit | kr882.72m |
Other Expenses | kr467.30m |
Earnings | kr415.42m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Oct 20, 2023
Earnings per share (EPS) | 4.11 |
Gross Margin | 72.77% |
Net Profit Margin | 34.25% |
Debt/Equity Ratio | 0% |
How did BIOG B perform over the long term?
See historical performance and comparison